A total of 200 AMI patients with diabetes mellitus at RIMS,RAIPUR were divided into two groups based on HDL–C level on admission: normal HDL–C group (HDL–C ≥ 40 mg/dL, n = 100) and low HDL–C group (HDL–C < 40 mg/dL, n = 100). The primary endpoint was 2–year major adverse cardiovascular events (MACE), defined as a composite of cardiac death, non–fatal myocardial infarction (MI), and target vessel revascularization (TVR).In patients with diabetes mellitus, low HDL–C remained an independent risk predictor for MACE after adjusting for multiple risk factors during 2–year follow–up of AMI.Our main findings of the present study are as follows: (1) 46.2% of diabetic patients presenting with AMI had a low HDL–C level; (2) 2–year clinical outcomes including MACE (mainly cardiac death and TVR) were poorer in diabetic patients with a low HDL–C level after AMI compared to those with a normal HDL–C level; (3) low HDL–C level remained an important risk predictor for MACE after adjusting for confounding clinicalfactors.